Erratum: Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: Analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls (Annals of the Rheumatic Diseases (2010) 69, (822-827) DOI:10.1136/ard.2009.111906);Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: Analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls

Annals of the Rheumatic Diseases

Volumn 69, Issue 5, 2010, Pages 822-827

  Arnett, Frank C ^a   Gourh, Pravitt ^a   Shete, Sanjay ^b   Ahn, Chul W ^a   Honey, Robert E ^a   Agarwal, Sandeep K ^a   Tan, Filemon K ^a   McNearney, Terry ^c   Fischbach, Michael ^d   Fritzler, Marvin J ^e   Mayes, Maureen D ^a   Reveille, John D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CENTROMERE ANTIBODY; DNA DIRECTED RNA POLYMERASE III; DNA TOPOISOMERASE; EPITOPE; FIBRILLARIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

AFRICAN AMERICAN; ALLELE; ARTICLE; CASE CONTROL STUDY; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE PREDISPOSITION; ETHNICITY; FEMALE; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HAPLOTYPE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; SEX DIFFERENCE; SKIN; SYSTEMIC SCLEROSIS;

EID: 77951517869     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.111906corr1     Document Type: Erratum

References (40)

1. Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006;367:1683-1691 (Pubitemid 43728250)
2. Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004;140:37-50. (Pubitemid 38055920)
3. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-205 (Pubitemid 18073738)
4. Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am 2003;29:239-254
5. Arnett FC. HLA and autoimmunity in scleroderma (systemic sclerosis). Int Rev Immunol 1995;12:107-128
6. Feghali-Bostwick C, Medsger TA Jr, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003;48:1956-1963 (Pubitemid 36828691)
7. Reveille JD, Fischbach M, McNearney T, et al. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 2001;30:332-346 (Pubitemid 32298859)
8. Arnett FC, Howard RF, Tan F, et al. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype. Arthritis Rheum 1996;39:1362-1370 (Pubitemid 26270096)
9. Gourh P, Tan FK, Assassi S, et al. Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis. Arthritis Rheum 2006;54:3945-3953 (Pubitemid 44955898)
10. Orozco G, Sánchez E, González-Gay MA, et al. Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum 2005;52:219-224 (Pubitemid 40129251)
11. Plenge RM, Padyukov L, Remmers EF, et al. Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet 2005;77:1044-1060 (Pubitemid 41698524)
12. Alkassab F, Gourh P, Tan FK, et al. An allograft inflammatory factor 1 (AIF1) single nucleotide polymorphism (SNP) is associated with anticentromere antibody positive systemic sclerosis. Rheumatology (Oxford) 2007;46:1248-1251 (Pubitemid 47244495)
13. Dieudé P, Guedj M, Wipff J, et al. Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum 2009;60:225-233
14. Kawaguchi Y, Tochimoto A, Ichikawa N, et al. Association of IL1A gene polymorphisms with susceptibility to and severity of systemic sclerosis in the Japanese population. Arthritis Rheum 2003;48:186-192 (Pubitemid 36091662)
15. Rueda B, Broen J, Simeon C, et al. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum Mol Genet 2009;18:2071-2077
16. Liakouli V, Manetti M, Pacini A, et al. The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis. Ann Rheum Dis 2009;68:584-590
17. Gladman DD, Keystone EC, Baron M, et al. Increased frequency of HLA-DR5 in scleroderma. Arthritis Rheum 1981;24:854-856
18. Briggs D, Welsh KI. Major histocompatibility complex class II genes and systemic sclerosis. Ann Rheum Dis 1991;50(Suppl 4):862-865
19. Gladman DD, Kung TN, Siannis F, et al. HLA markers for susceptibility and expression in scleroderma. J Rheumatol 2005;32:1481-1487 (Pubitemid 41113968)
20. Kuwana M, Inoko H, Kameda H, et al. Association of human leukocyte antigen class II genes with autoantibody profiles, but not with disease susceptibility in Japanese patients with systemic sclerosis. Intern Med 1999;38:336-344
21. Kuwana M, Okano Y, Kaburaki J, et al. HLA class II genes associated with anticentromere antibody in Japanese patients with systemic sclerosis (scleroderma). Ann Rheum Dis 1995;54:983-987
22. Kang SH, Park MH, Song EY, et al. Association of HLA class II genes with systemic sclerosis in Koreans. J Rheumatol 2001;28:1577-1583 (Pubitemid 32660631)
23. Reveille JD, Durban E, MacLeod-St Clair MJ, et al. Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis). J Clin Invest 1992;90:973-980
24. Arnett FC, Reveille JD, Goldstein R, et al. Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis Rheum 1996;39:1151-1160 (Pubitemid 26240228)
25. Reveille JD, Owerbach D, Goldstein R, et al. Association of polar amino acids at position 26 of the HLA-DQB1 first domain with the anticentromere autoantibody response in systemic sclerosis (scleroderma). J Clin Invest 1992;89:1208-1213
26. Marguerie C, Bunn CC, Copier J, et al. The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine (Baltimore) 1992;71:327-336
27. Morel PA, Chang HJ, Wilson JW, et al. Severe systemic sclerosis with anti-topoisomerase I antibodies is associated with an HLA-DRw11 allele. Hum Immunol 1994;40:101-110 (Pubitemid 24209007)
28. Falkner D, Wilson J, Fertig N, et al. Studies of HLA-DR and DQ alleles in systemic sclerosis patients with autoantibodies to RNA polymerases and U3-RNP (fibrillarin). J Rheumatol 2000;27:1196-1202 (Pubitemid 30262504)
29. Kuwana M, Kaburaki J, Arnett FC, et al. Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum 1999;42:465-474 (Pubitemid 29136094)
30. Reveille JD, Brady J, MacLeod-St Clair M, et al. HLA-DPB1 alleles and autoantibody subsets in systemic lupus erythematosus, Sjögren's syndrome and progressive systemic sclerosis: a question of disease relevance. Tissue Antigens 1992;40:45-48
31. Gilchrist FC, Bunn C, Foley PJ, et al. Class II HLA associations with autoantibodies in scleroderma: a highly significant role for HLA-DP. Genes Immun 2001;2:76-81. (Pubitemid 33674232)
32. Stephens CO, Briggs DC, Vaughan RW, et al. The HLA-DP locus in systemic sclerosis - no primary association. Tissue Antigens 1993;42:144-145
33. Mayes MD. The establishment and utility of a population-based registry to understand the epidemiology of systemic sclerosis. Curr Rheumatol Rep 2000;2:512-516
34. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-590
35. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc 1995;57:289-300.
36. Schreuder GM, Hurley CK, Marsh SG, et al. HLA dictionary 2004: summary of HLA-A, -B, -C, -DRB1/3/4/5, -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR, and -DQ antigens. Hum Immunol 2005;66:170-210.
37. Lambert NC, Distler O, Müller-Ladner U, et al. HLA-DQA1*0501 is associated with diffuse systemic sclerosis in Caucasian men. Arthritis Rheum 2000;43:2005-2010
38. Fanning GC, Welsh KI, Bunn C, et al. HLA associations in three mutually exclusive autoantibody subgroups in UK systemic sclerosis patients. Br J Rheumatol 1998;37:201-207 (Pubitemid 28375191)
39. Kuwana M, Pandey JP, Silver RM, et al. HLA class II alleles in systemic sclerosis patients with anti-RNA polymerase I/III antibody: associations with subunit reactivities. J Rheumatol 2003;30:2392-2397 (Pubitemid 37413899)
40. Saltini C, Amicosante M, Franchi A, et al. Immunogenetic basis of environmental lung disease: lessons from the berylliosis model. Eur Respir J 1998;12:1463-1475 (Pubitemid 29011448)